New York, February 16, 2026, 14:14 (EST) — Market closed.
- AbbVie finished Friday at $231.50, a gain of roughly 1.8%.
- U.S. markets will stay closed Monday for Washington’s Birthday, reopening for trading on Tuesday.
- AbbVie’s next cash dividend lands Tuesday, just as investors gear up for a packed week of U.S. data releases.
AbbVie (ABBV) finished Friday at $231.50 per share, gaining 1.8%. U.S. equity trading paused Monday for Washington’s Birthday, with the New York Stock Exchange closed.
With the holiday cramming the week, investors are forced to recalibrate on Tuesday. U.S. retail sales data drop before the open; then, on Wednesday afternoon, the Federal Reserve releases its meeting minutes. (Scotiabank)
AbbVie will hand out its regular $1.73 per share dividend on Tuesday, a move that’s closely watched by income-focused funds, even though it leaves the stock’s intrinsic value untouched. (dividendmax.com)
AbbVie, earlier this month, put its sights on 2026 adjusted earnings of $14.37 to $14.57 per share—those figures exclude certain one-offs—and projected Skyrizi and Rinvoq together pulling in roughly $31.6 billion in sales that year. But William Blair’s Matt Phipps flagged persistent investor worries over intensifying competition. AbbVie CFO Scott Reents also mentioned “low-single-digit pricing headwinds” for both drugs. (Reuters)
AbbVie turned in fourth-quarter revenue of $16.618 billion, with adjusted EPS coming in at $2.71. CEO Robert Michael told investors he’s looking for “another year of robust growth in 2026.” (AbbVie News Center)
This month, the company moved to expand Rinvoq’s reach, filing with both U.S. and European regulators for a vitiligo nod, citing late-stage study results. (AbbVie News Center)
Policy risk still looms for the group. Last week, AbbVie filed a lawsuit against the U.S. Department of Health and Human Services, pushing back on Medicare’s drug price negotiation program and specifically contesting Botox’s inclusion. The company claims Botox should be excluded; it made up a bit more than 10% of AbbVie’s revenue last year, according to the report. (Reuters)
When Wall Street opens Tuesday, the focus turns to whether the stock responds to fresh macro numbers like retail sales, or snaps back to drug-pricing developments. Next up: AbbVie’s dividend payout, set for Tuesday, February 17.
